Healthpeak Properties (NYSE:DOC) Rating Increased to Hold at Wall Street Zen

Healthpeak Properties (NYSE:DOC) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

DOC has been the topic of a number of other research reports. Argus lowered Healthpeak Properties from a “buy” rating to a “hold” rating in a report on Thursday. Wells Fargo & Company restated a “positive” rating on shares of Healthpeak Properties in a research report on Tuesday. Weiss Ratings upgraded shares of Healthpeak Properties from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 26th. The Goldman Sachs Group initiated coverage on shares of Healthpeak Properties in a research note on Friday, January 9th. They issued a “neutral” rating and a $17.00 price objective for the company. Finally, Cantor Fitzgerald set a $17.00 target price on shares of Healthpeak Properties in a research report on Monday, January 5th. Six investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $19.42.

Healthpeak Properties Stock Performance

NYSE DOC opened at $16.86 on Friday. The company has a fifty day moving average of $16.87 and a two-hundred day moving average of $17.60. The company has a market capitalization of $11.72 billion, a PE ratio of 168.62, a P/E/G ratio of 8.95 and a beta of 1.12. Healthpeak Properties has a 1 year low of $15.71 and a 1 year high of $21.28. The company has a debt-to-equity ratio of 1.21, a current ratio of 2.82 and a quick ratio of 1.22.

Healthpeak Properties (NYSE:DOC) last posted its quarterly earnings data on Monday, February 2nd. The real estate investment trust reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.02. Healthpeak Properties had a net margin of 2.52% and a return on equity of 0.84%. The company had revenue of $719.40 million for the quarter, compared to analyst estimates of $685.14 million. During the same period in the previous year, the business posted $0.46 earnings per share. Healthpeak Properties’s quarterly revenue was up 3.1% on a year-over-year basis. Healthpeak Properties has set its FY 2026 guidance at 1.700-1.740 EPS. As a group, analysts expect that Healthpeak Properties will post 1.86 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Mather Group LLC. purchased a new stake in shares of Healthpeak Properties in the third quarter worth about $25,000. City Holding Co. acquired a new position in Healthpeak Properties during the 3rd quarter worth approximately $26,000. WPG Advisers LLC boosted its holdings in Healthpeak Properties by 270.2% in the 4th quarter. WPG Advisers LLC now owns 1,640 shares of the real estate investment trust’s stock worth $26,000 after acquiring an additional 1,197 shares during the period. Rexford Capital Inc. acquired a new stake in Healthpeak Properties in the second quarter valued at approximately $28,000. Finally, Sound Income Strategies LLC acquired a new stake in Healthpeak Properties in the third quarter valued at approximately $28,000. 93.57% of the stock is owned by institutional investors and hedge funds.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.